Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 5, 2004, Pages 410-417

  Cuffari, Carmen ^a,c   Dassopoulos, Themistocles ^a   Turnbough, Lisa ^a   Thompson, Richard E ^b   Bayless, Theodore M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

6 mercaptopurine; 6 methyl mercaptopurine; 6 MMP; 6 MP; 6 TGn; 6 thioguanine ribonucleotide; AZA; azathioprine; Harvey Bradshaw index; HBI; pharmacokinetic analysis; PKA; thiopurine methyltransferase; TPMT

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ERYTHROCYTE ENZYME; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FEVER; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALAISE; MALE; METABOLITE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; TUBERCULOUS ARTHRITIS; ULCERATIVE COLITIS; VOMITING;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; ERYTHROCYTES; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; METHYLTRANSFERASES; PROSPECTIVE STUDIES; REMISSION INDUCTION; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 2342420871     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00127-2     Document Type: Article

References (36)

1. Candy S., Wright J., Gerger M., Adams G., Gerig M., Goodman R. A controlled double-blind study of azathioprine in the management of Crohn's disease. Gut. 37:1995;674-678
2. Ewe K., Press A.G., Singe C.C., Stufler M., Ueberschaer B., Hommel G., Buschenfelde K.H.M.Z. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 105:1993;367-372
3. Present D.H., Korelitz B.I., Wisch N. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 302:1989;981-987
4. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn's disease a meta-analysis. Ann Intern Med. 122:1995;132-142
5. Elion G.B. The pharmacology of azathioprine. Ann N Y Acad Sci. 21:1977;401-407
6. Fairchild C.R., Maybaum J., Kennedy K.A. Concurrent unilateral chromatid damage and DNA strand breaks in response to 6-thioguanine treatment. Biochem Pharmacol. 35:1986;3533-3541
7. Christie N.T., Drake S., Meyn R.E. 6-Thioguanine induced DNA damage as a determinant of cytotoxicity in cultured hamster ovary cells. Cancer Res. 44:1986;3665-3671
8. Dimitriu A., Fauci A.S. Activation of human B lymphocytes. Differential effects of azathioprine on B lymphocytes and lymphocyte subpopulations regulating B cell function. J Immunol. 121:1978;2335-2339
9. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., Lehr H.A., Wirtz S., Becker C., Atreya R., Mudter J., Hildner K., Basrtsch B., Holtmann, Blumberg R., Walczak H., Iven H., Galle P.R., Ahmadian M.R., Neurath M.F. CD-28-dependent Rac 1 activation is the molecular target of azathioprine in primary human CD4 T lymphocytes. J Clin Invest. 111:2003;1133-1145
10. Alves S., Prata M.J., Ferreira F., Amorim A. Screening of thiopurine methyl s-transferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum Mutat. 15:2000;246-253
11. Weinshilboum R.N., Sladek S.L. Mercaptopurine pharmacogenetics monogenic inheritance of erythrocyte thiopurine methyl transferase activity. Am J Hum Genet. 32:1980;651-662
12. Lennard L. The clinical pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Eur J Clin Pharmacol. 43:1992;329-339
13. Lennard L., Lilleyman J.S. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 7:1989;1816-1823
14. Evans W.E., Homer M., Chu Y.Q. Altered mercaptopurine metabolism, toxic effects, and dosage requirements in a thiopurine methyl transferase deficient child with acute lymphoblastic leukemia. J Pediatr. 119:1991;985-989
15. McLeod H.L., Relling M.V., Liu Q., Pui C.H., Evans W.E. Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 85:1995;1897-1902
16. Kaskas B.A., Louis E., Hindorf U., Schaeffeler E., Deflandre J., Graepler I., Schmiegelow K., Gregor M., Zanger U.M., Eichelbaum M., Schwab M. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut. 52:2003;140-142
17. Bostrom B., Erdman G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 15:1993;80-86
18. Ansari A., Hassan C., Duley J., Marinaki A., Shobowale-Bakre E.M., Seed P., Meenan J., Yim A., Sanderson J. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 16:2002;1743-1750
19. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., Seidman E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 118:2000;705-713
20. Szumlanski C., Weinshilboum R.M. Sulphasalazine inhibition of thiopurine methyltransferase possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Pharmacol. 39:1995;1505-1506
21. Lowry P.W., Franklin C.L., Weaver A.L., Szumlanski C., Mays D.C., Loftus E.V., Tremaine W.J., Lipsky J.J., Weinshilboum R.M., Sandborn W.J. Leukopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine or balsalazide. Gut. 49:2001;656-664
22. Black A.J., McLeod H.L., Capell H.A. Thiopurine methyl transferase predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 129:1998;716-718
23. Dervieux T., Blanco J.G., Krynetski E.Y., Vanin E.F., Roussel M.F., Relling M.V. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 61:2001;5810-5816
24. Cuffari C., Theoret Y., Latour S., Seidman E.G. 6-mercaptopurine metabolism in Crohn's disease correlation with efficacy and toxicity. Gut. 39:1996;401-406
25. Harvey R.F., Bradshaw J.M. A simple index of Crohn's disease activity. Lancet. 1:1980;514
26. Truelove S.C., Witts L. Cortisone in ulcerative colitis final report on a therapeutic trial. BMJ. 2:1955;1041-1048
27. Kombluth A., Sachar D.B., Salomon P. Crohn's disease. Sleisenger M.H., Fordtran J.S. Gastrointestinal diseases. 1998;1708-1734 WB Saunders, Philadelphia
28. O'Brien J.J., Bayless T.M., Bayless J.A. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 101:1991;39-46
29. Cuffari C., Hunt S., Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut. 48:2001;591-592
30. Szumlanski C., Honchel R., Scott M.C., Weinshilboum R.M. Human liver thiopurine methyl transferase pharmacogenetics biochemical properties, liver erythrocyte correlation and presence of isozymes. Pharmacogenetics. 2:1992;148159
31. Sandborn W.J., Tremaine W.J., Wolfe D.C., Van Os E.C., Zins B.J., Mays D.C., Lipsky J.J. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 117:1999;527-535
32. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., Vasiliauskas E. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 122:2002;904-915
33. Colonna T., Korelitz B. The role of leukopenia in 6-mercaptopurine- induced remission of refractory Crohn's disease. Am J Gastroenterol. 89:1993;362-366
34. Garza A., Sninsky C.A. Changes in red cell mean corpuscular volume (MCV) during azathioprine or 6-mercaptopurine therapy for Crohn's disease may indicate optimal dose titration. Gastroenterology. 120:2001;A3166
35. Achar J.P., Stevens T., Brzezinski A., Seidner D., Lashner B. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopruine and azathioprine therapy. Am J Gastroenterol. 95:2000;A272
36. Cuffari C., Harris M.L., Shih C., Turnbough L., Bayless T.M. High erythrocyte azathioprine metabolite (6-TG) metabolite levels associate with an improved maintenance of clinical response to infliximab therapy. Gastroenterology. 124:2003;A11